×
About 727 results

ALLMedicine™ Chemical Burns Center

Research & Reviews  355 results

Treatment of Oculoplastic and Ocular Surface Disease in Eyes Implanted with a Type I Bo...
https://doi.org/10.1007/s12325-020-01381-3
Advances in Therapy; Zhang Y, Ou Z et. al.

May 21st, 2020 - This study aimed to describe the clinical features, surgical management of the eyelid and ocular surface, and outcomes of 16 patients implanted with a Boston type I keratoprosthesis (KPro). A retrospective, single-center, consecutive case series o...

Polymodal Sensory Transduction in Mouse Corneal Epithelial Cells.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7401707
Investigative Ophthalmology & Visual Science; Lapajne L, Lakk M et. al.

Apr 9th, 2020 - Contact lenses, osmotic stressors, and chemical burns may trigger severe discomfort and vision loss by damaging the cornea, but the signaling mechanisms used by corneal epithelial cells (CECs) to sense extrinsic stressors are not well understood. ...

Enzymatic debridement as an effective treatment for combined flame and chemical burns c...
https://doi.org/10.1016/j.ajem.2020.02.030
The American Journal of Emergency Medicine; Claes KEY, Vyncke T et. al.

Feb 18th, 2020 - Since its introduction on the market in 2007, the number of reports on injuries caused by the ignition or explosion of electronic nicotine delivery systems (ENDS) has increased significantly. Two male patients have been treated at our burn center,...

Long-term visual outcomes of the Boston type I keratoprosthesis in Canada.
https://doi.org/10.1136/bjophthalmol-2019-315345
The British Journal of Ophthalmology; Szigiato AA, Bostan C et. al.

Feb 16th, 2020 - To evaluate long-term visual outcomes of Boston type I keratoprosthesis (KPro) surgery and identify risk factors for visual failure. Single surgeon retrospective cohort study including 85 eyes of 74 patients who underwent KPro implantation to trea...

Early Application of Bevacizumab After Sclerocorneal Grafting for Patients With Severe ...
https://doi.org/10.1097/ICO.0000000000002272
Cornea Huang ST, Zhou T et. al.

Feb 6th, 2020 - To investigate whether subconjunctival bevacizumab help prevent corneal graft neovascularization and prolong the graft survival of patients with chemical burns. We performed a prospective nonrandomized comparative case series study. Twenty-six eye...

see more →

Clinicaltrials.gov  363 results

Treatment of Oculoplastic and Ocular Surface Disease in Eyes Implanted with a Type I Bo...
https://doi.org/10.1007/s12325-020-01381-3
Advances in Therapy; Zhang Y, Ou Z et. al.

May 21st, 2020 - This study aimed to describe the clinical features, surgical management of the eyelid and ocular surface, and outcomes of 16 patients implanted with a Boston type I keratoprosthesis (KPro). A retrospective, single-center, consecutive case series o...

Polymodal Sensory Transduction in Mouse Corneal Epithelial Cells.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7401707
Investigative Ophthalmology & Visual Science; Lapajne L, Lakk M et. al.

Apr 9th, 2020 - Contact lenses, osmotic stressors, and chemical burns may trigger severe discomfort and vision loss by damaging the cornea, but the signaling mechanisms used by corneal epithelial cells (CECs) to sense extrinsic stressors are not well understood. ...

Enzymatic debridement as an effective treatment for combined flame and chemical burns c...
https://doi.org/10.1016/j.ajem.2020.02.030
The American Journal of Emergency Medicine; Claes KEY, Vyncke T et. al.

Feb 18th, 2020 - Since its introduction on the market in 2007, the number of reports on injuries caused by the ignition or explosion of electronic nicotine delivery systems (ENDS) has increased significantly. Two male patients have been treated at our burn center,...

Long-term visual outcomes of the Boston type I keratoprosthesis in Canada.
https://doi.org/10.1136/bjophthalmol-2019-315345
The British Journal of Ophthalmology; Szigiato AA, Bostan C et. al.

Feb 16th, 2020 - To evaluate long-term visual outcomes of Boston type I keratoprosthesis (KPro) surgery and identify risk factors for visual failure. Single surgeon retrospective cohort study including 85 eyes of 74 patients who underwent KPro implantation to trea...

Early Application of Bevacizumab After Sclerocorneal Grafting for Patients With Severe ...
https://doi.org/10.1097/ICO.0000000000002272
Cornea Huang ST, Zhou T et. al.

Feb 6th, 2020 - To investigate whether subconjunctival bevacizumab help prevent corneal graft neovascularization and prolong the graft survival of patients with chemical burns. We performed a prospective nonrandomized comparative case series study. Twenty-six eye...

see more →

News  9 results

Ocular Chemical Burns in the Dermatology Office: A Practical Approach to Managing Safety Precautions
https://www.mdedge.com/dermatology/article/202365/aesthetic-dermatology/ocular-chemical-burns-dermatology-office-practical/page/0/1?channel=177

Jun 5th, 2019 - Symptoms of Ocular Chemical Exposure Signs and symptoms associated with ocular chemical exposures include erythema, pain, tearing, photosensitivity, eyelid swelling, foreign body sensation, changes in vision, and corneal clouding. 3,5,9,28 Specifi.

Europe approves Western world's first stem-cell therapy for rare eye condition
https://www.reuters.com/article/us-health-stemcells-europe/europe-approves-western-worlds-first-stem-cell-therapy-for-rare-eye-condition-idUSKBN0LO18X20150220

Feb 20th, 2015 - (Reuters) - Europe has approved the Western world’s first medicine containing stem cells to treat a rare condition caused by burns to the eye, marking a milestone in the use of the technology. Holoclar, from privately held Italian company Chiesi, ...

Europe recommends approval for first stem-cell therapy
https://www.reuters.com/article/us-health-stemcells-europe/europe-recommends-approval-for-first-stem-cell-therapy-idUSKBN0JX1CH20141219

Dec 19th, 2014 - LONDON (Reuters) - European regulators have recommended approval of the first medicine containing stem cells to treat a rare condition caused by burns to the eye. The European Medicines Agency said on Friday that Holoclar, from privately held Ital...

Topical Pain Relievers: FDA Issues Burn Warning
https://www.mdedge.com/neurology/article/56029/rheumatology/topical-pain-relievers-fda-issues-burn-warning
Elizabeth Mechcatie

Sep 20th, 2012 - Rare cases of chemical burns caused by over-the-counter topical muscle and joint pain relievers has prompted the Food and Drug Administration to issue an advisory about the use of the products, with recommendations for both consumers and health pr.

see more →